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ABSTRACT
Cushing’s syndrome (CS) during pregnancy is a rare condition with fewer
than 150 cases reported in the literature. Adrenal adenomas were found to
be the commonest cause, followed by Cushing’s disease. The gestation dra-
matically affects the maternal hypothalamic–pituitary–adrenal axis, resulting
in increased hepatic production of corticosteroid-binding globulin (CBG),
increased levels of serum, salivary and urinary free cortisol, lack of suppres-
sion of cortisol levels after dexamethasone administration and placental
production of CRH and ACTH. Moreover, a blunted response of ACTH and
cortisol to exogenous CRH may also occur. Therefore, the diagnosis of CS
during pregnancy is much more difficult. Misdiagnosis of CS is also com-
mon, as the syndrome may be easily confused with preeclampsia or gesta-
tional diabetes. Because CS during pregnancy is usually associated with
severe maternal and fetal complications, its early diagnosis and treatment
are critical. Surgery is the treatment of choice for CS in pregnancy, except
perhaps in the late third trimester, with medical therapy being a second
choice. There does not seem to be a rationale for supportive treatment
alone. (Arq Bras Endocrinol Metab 2007;51/8:1293-1302)
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RESUMO
Síndrome de Cushing na Gravidez: Uma Visão Geral.
A ocorrência de síndrome de Cushing (SC) durante a gravidez é rara, com
menos de 150 casos reportados na literatura. Os adenomas adrenais
parecem ser a causa mais comum seguidos da doença de Cushing. A
gestação afeta de maneira dramática o eixo hipotálamo–hipófise–adrenal
materno resultando em aumento da produção hepática da globulina
ligadora de corticosteróides (CBG), aumento dos níveis séricos, salivares e
livres urinários de cortisol, falta de supressão do cortisol após
administração de dexametasona e produção placentária de CRH e ACTH.
Além disso, pode também ocorrer bloqueio da resposta do ACTH e do
cortisol ao CRH exógeno. Assim, o diagnóstico de SC durante a gravidez
torna-se muito mais difícil. A falha em diagnosticar SC é também comum,
já que a síndrome pode ser facilmente confundida com pré-eclampsia ou
diabetes gestacional. Uma vez que a SC de ocorrência na gravidez é
usualmente associada com graves complicações materno-fetais, seu
diagnóstico e tratamento precoces tornam-se críticos. A cirurgia é o
tratamento de escolha para a SC na gravidez, exceto, talvez, no final do 3º
trimestre, sendo o tratamento medicamentoso a segunda escolha. Não
parece haver nenhum arrazoado para o tratamento de suporte
isoladamente. (Arq Bras Endocrinol Metab 2007;51/8:1293-1302)
Descritores: Síndrome de Cushing; Doença de Cushing; Adenoma
adrenal; Gravidez
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PREGNANCY IS UNCOMMON IN WOMEN with Cush-ing’s syndrome (CS), with fewer than 150 cases
reported in the world literature, as hyperandrogenism
and hypercortisolism suppress pituitary secretion of
gonadotropins (1,2). However, because CS results in
increased fetal and maternal complications, its early
diagnosis and treatment are critical.
The hypothalamic–pituitary–adrenal (HPA) axis
exerts profound, mostly inhibitory effects, on the
reproductive axis, with corticotropin-releasing hormone
(CRH) and CRH-induced proopio-melanocortin pep-
tides inhibiting hypothalamic GnRH secretion, and
glucocorticoids inhibiting pituitary LH and ovarian
estrogen and progesterone secretion and rendering
estrogen-target tissues, such as the endometrium, resis-
tant to gonadal steroids (4,5). These effects at the HPA
axis are responsible for the “hypothalamic” amenorrhea
of stress, depression and eating disorders, and the
hypogonadism of CS (6,7). Moreover, CRH, the prin-
cipal regulator of the HPA axis, has been identified in
most female reproductive tissues including the uterus,
the placenta, and the ovary. Placental CRH may partic-
ipate in the physiology of pregnancy, in late pregnancy
complications such as preterm labor and preeclampsia,
and also in the onset of parturition. Increased levels of
unbound placental CRH may be responsible for the
hypercortisolism of the second half of pregnancy. This
hypercortisolism is followed by a transient suppression
of hypothalamic CRH secretion in the postpartum
period. This may explain the depressive states frequent-
ly observed in the postpartum period (4-7).
The clinical diagnosis of CS during pregnancy
may be missed because of the overlapping features of
weight gain, hypertension, fatigue, hyperglycemia, and
emotional changes that occur in normal pregnancy.
The biochemical diagnosis is difficult to establish due
to the normal hypercortisolism of pregnancy (2,8).
Indeed, pregnancy is associated with a state of
increased HPA axis activity as shown by elevations in
urinary free cortisol (UFC), total and free plasma cor-
tisol, and corticosteroid-binding globulin (CBG) val-
ues (8). Also, during late pregnancy the adrenal glands
have increased responsiveness to ACTH compared
with non-pregnant women (8).
HORMONAL CHANGES IN HPA AXIS 
DURING PREGNANCY
Gestation dramatically affects the maternal HPA axis.
Increasing placental secretion of estrogen stimulates
the production of CBG by the liver, thus stimulating
cortisol production and increasing circulating levels of
bound cortisol (8). However, both circulating and
UFC levels also increase steadily during gestation,
reaching values similar to those found in CS (3,8).
Indeed, total and free plasma cortisol concentrations
rise in parallel across gestation, with plasma cortisol
reported to be 2- to 3-fold higher in comparison with
non-pregnant controls (2,8-10). The increase in plas-
ma cortisol occurs as early as the 11th week of gesta-
tion (9), reaching a peak between the first and second
trimesters, and a plateau in the third trimester (11).
The hepatic production of CBG remains elevated until
at least the 12th postpartum day (8). Salivary cortisol,
another measure of plasma free cortisol, is more than
2-fold increased compared with non-pregnant controls
in the third trimester (8,12). The circadian rhythm of
cortisol is preserved but may be partly blunted (8,12).
UFC excretion parallels the rise in serum corti-
sol through the course of gestation (2,8). Mean 24-h
UFC is elevated at least 180% during gestation com-
pared with non-pregnant levels (13). Among 15 nor-
mal pregnant women, the mean UFC excretion rate
in the third trimester ranged from 188 to 696
nmol/day or 68 µg/day (mean, 350 nmol/day or
127 µg/day) (14).
It was also demonstrated in late pregnancy and
early post-partum that dexamethasone does not sup-
press plasma and urinary cortisol to the same degree as
in the non-pregnant state (2,15). Odagiri et al. (10)
demonstrated a 40% vs. 87% suppression of plasma
cortisol and similar effects on UFC after 1 mg dexam-
ethasone in normal second- to third-trimester preg-
nancy compared with controls. Advancing gestation is
associated with increasing lack of suppression after 1
mg dexamethasone (10). This phenomenon has been
attributed to CBG effects on cortisol, tissue refractori-
ness to glucocorticoids, and resetting of the maternal
HPA feedback mechanism (8,10). Others suggest that
the anti-glucocorticoid effects of progesterone might
contribute to tissue resistance (8,10).
It should also be noted that the fetus is protect-
ed in early gestation from the effects of maternal
hypercortisolism by placental 11β-hydroxysteroid
dehydrogenase 2 (11β-HSD2), which converts active
glucocorticoids — cortisol and corticosterone — to
their inactive 11-keto-metabolites (8,16).
Plasma ACTH levels rise throughout pregnan-
cy, reaching a peak during labor and delivery (8). In
one study, levels increased almost 3-fold from the end
of the first to the third trimester (23–59 pg/mL, mea-
sured by RIA; 5–13 pmol/liter) (17). Compared to
healthy non-pregnant women, basal plasma ACTH
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levels in pregnancy have been varyingly reported as
low (17,18) or high (19). Placentally derived ACTH
may be a significant contributor to hypercortisolism in
pregnancy (8).
The cause of ACTH increase during pregnancy
is not clear, but may include placental synthesis and
release of biologically active CRH and ACTH, pitu-
itary desensitization to cortisol feedback, or enhanced
pituitary responses to corticotropin-releasing factors
such as vasopressin and CRH (3,8).
Placental CRH, isolated in 1988 by Sasaki et al.
(20), is identical to hypothalamic CRH in structure,
immunoreactivity, bioactivity, and transcriptional sites
(4). Plasma CRH levels rise exponentially by 1,000-
fold as gestation progresses (4), beginning around 8-
wk gestation (21,22). At the 35th week there is a sharp
increase to a peak of 4,000 pg/mL at 40-week gesta-
tion (23,24), with normalization to non-pregnant val-
ues within 24 h of delivery (8,25,26).
Blunted response of ACTH and cortisol to
exogenous CRH may also occur. In the series by
Schulte et al. (27), intravenous administration of human
CRH (1 µg/kg) failed to increase plasma cortisol or
ACTH in seven pregnant women one week before their
expected delivery date. In contrast, a prompt ACTH
response to CRH was observed when the same women
were studied at 4–5 week postpartum. Other investiga-
tors using a higher dose (2 µg/kg) during third
trimester pregnancies demonstrated similar ACTH and
cortisol increments to those of non-pregnant women
(28). These observations are consistent with the
hypothesis that impaired CRH response may be due to
high endogenous cortisol concentrations with desensiti-
zation of the pituitary corticotrophs (8,27).
The HPA axis during parturition and 
post-partum period
Plasma CRH, ACTH, and cortisol concentrations
increase several-fold with the onset of labor and
delivery (8,17,29,30). Peak CRH levels are found
within 48 h before delivery and fall during labor,
consistent with a preeminent role for CRH in partu-
rition (8,31).
In the immediate post-partum period, plasma
CRH, ACTH, and cortisol levels decrease rapidly
toward the non-pregnant range, consistent with their
biological half-lives (8). Both CRH and ACTH nor-
malize within 2 h from delivery whereas normalization
of plasma cortisol levels is more protracted (8,32). In
one series, mean post-partum 24-h plasma cortisol lev-
els were 5.4 µg/dL (149 nmol/liter), whereas these
values in the second and third trimesters were 18.8
µg/dL (518 nmol/liter) and 20.3 µg/dL (560
nmol/liter), respectively (13).
Lack of normal cortisol suppression after 1 mg
of dexamethasone is quite common in the immediate
postpartum and was found in 82% of women evaluat-
ed by Greenwood and Parker (33). This abnormality
may persist until the 5th postpartum week (34).
CUSHING’S SYNDROME DURING 
PREGNANCY
Frequency
CS is rarely associated with pregnancy, probably
because hypercortisolism prevents normal follicular
development and ovulation (2,8). The first description
of CS occurring in pregnancy was reported by Hunt
and McConahey, in 1953 (35). Since then, at least
140 pregnancies have been reported in 126 subjects as
individual cases and small case series (1,3,8,36,37).
Multiple pregnancies occurred in about 10% of the
patients (8,9,39). The mean gestational age at diagno-
sis is approximately 18 weeks (3,8).
Etiology
The etiology of CS differs between the pregnant and
non-pregnant state. Indeed, adrenal adenomas under-
lie a disproportionately high proportion of CS cases,
accounting for approximately 40–50% of cases in preg-
nancy (8,39-41), in comparison with 17–29% in non-
pregnant women (42-44). Conversely, Cushing’s dis-
ease appears to be less common in pregnancy, with
rates of 63–72% in the general population (42-44),
compared with 33% in 122 pregnant women
(8,39,41,45). Ectopic ACTH secretion has been
reported to cause CS in four patients, two of whom
had a diagnosis of pheochromocytoma (46,47).
Pheochromocytoma also was associated with one case
of apparent ACTH-independent hypercortisolism in
pregnancy (48). The increased incidence of adrenal CS
in pregnancy is not understood (8). It is possible that
women with Cushing’s disease are less ovulatory than
those with primary adrenal disease, perhaps because
they are more hyperandrogenic (8,49). Another likely
explanation is that unrecognized illicit LH/hCG
receptor expression was considered to be adrenal ade-
noma (50,51). Most patients with ectopic ACTH
secretion have severe hypercortisolism and amenor-
rhea, which probably accounts for the reduced preva-
lence of this condition in pregnancy (8,46,47).
There have been a few reports of recurrent CS
during pregnancy that spontaneously remitted after
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delivery (15,38,52). CS induced by pregnancy seems
to be caused by a product(s) of the feto-placental unit.
Such a compound may act either by 1) stimulation of
the maternal pituitary to produce ACTH, which, in
turn, stimulates the adrenals; 2) direct stimulation of
the maternal adrenal glands; or 3) activation of an
ectopic source of either an adrenal or pituitary stimu-
lator. Direct stimulation of the maternal adrenals may
be the result of either an abnormally high level of an
adrenal-stimulating product of the feto-placental unit
or unusual responsiveness of the adrenals to normal
pregnancy levels of an adrenal stimulator. Several pla-
cental peptides could be considered as candidate stim-
ulators such as placental CRF, placental ACTH, or an
as yet undefined compound (15).
Maternal and fetal morbidity and mortality
CS is associated with significant maternal morbidity and
mortality in approximately 70% of cases. The most com-
mon complications in pregnancy are hypertension and
diabetes or impaired glucose tolerance (8,40,48, 53). In
smaller numbers of cases, pregnancies were associated
with poor wound healing, osteoporosis, fracture, severe
psychiatric complications, maternal cardiac failure, and
death (8,54-56) (table 1). Maternal death is rare and
one death was reported in the month after delivery as a
result of cerebrovascular disease and disseminated
intravascular coagulation caused by pheochromocytoma
(47). Another woman died due to complications from
adrenalectomy and cesarean-section (57).
In a review of 65 pregnancies in patients with
CS Buescher et al. (40) found hypertension in two-
thirds of the pregnancies, glucose intolerance in one-
third, and preeclampsia in approximately 10%; more-
over, three maternal deaths were reported. Maternal
morbidity was apparently more severe in patients with
adrenal neoplasms than in those with pituitary disease.
Maternal outcomes, however, can be improved by
reversal of the hypercortisolism (39).
Fetal complications include early spontaneous
abortions, the rate of which may be underestimated
because of delay in the diagnosis of CS (8,37,39). Pre-
mature labor (20 to 38 weeks of gestation) is common
and has been reported in up to 60% of pregnancies
(3,8). Consequently, a pregnancy complicated by CS
is a high-risk obstetric condition. Fetal mortality and
morbidity are primarily related to prematurity.
Intrauterine growth retardation is also common. In
the series of 65 pregnancies in patients with CS (40),
perinatal death was reported in 15.4%, and stillbirth
accounted for half the cases. In that same series,
intrauterine growth restriction was seen in 26.2% (40).
In a comparison of the fetal outcomes in CS, Pickard
et al. (41) observed more pregnancies reaching term
with less prematurity, a lower abortion rate, and fewer
cases of stillbirth in patients with Cushing’s disease
than in those with CS due to adrenal adenoma or car-
cinoma. In a series of 136 pregnancies complicated by
CS there were 107 (79%) live births (3); 43% of births
were premature. There were eight stillbirths, six
intrauterine deaths/spontaneous abortions, and one
ectopic pregnancy. Six therapeutic abortions were
undertaken, and in three cases the outcome was uncer-
tain. One infant died from respiratory distress and hya-
line membrane disease (58). Intraventricular hemor-
rhage caused another infant death (69). Viardot et al.
(60) reported two cases of pregnancy in patients with
CS, who developed a severe, sudden and early HELLP
syndrome (hemolytic anemia, elevated liver enzymes
and low platelet count), which eventually progressed
to fetal death. Fetal adrenal insufficiency occurs rarely,
and signs of glucocorticoid excess have not been
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Table 1. Frequency of maternal and fetal complications arising in CS during pregnancy.
Maternal morbidity Fetal morbidity
Hypertension (68%) Prematurity (43%)
Diabetes or impaired glucose tolerance (25%) Stillbirths (6%)
Preeclampsia (14%) Spontaneous abortion/intrauterine death (5%)
Osteoporosis and fracture (5%) Infant death in two cases (acute hepatitis; 
sepsis and gastroenteritis)
Cardiac failure (3%) Intrauterine growth retardation (21%)
Psychiatric disorders (4%) Hypoadrenalism (2%)
Wound infection (2%) Single reports of cleft lip, patent ductus and
coarctation
Maternal death (2%) Intraventricular hemorrhage in two cases 
postpartum
Adapted from Ref. 8
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reported, suggesting that placental degradation of cor-
tisol protects the fetus (8,58). Congenital malforma-
tions are also rare (8). For example, Fayol et al. (61)
presented a case of transient hypertrophic obstructive
cardiomyopathy in a newborn whose mother had
hypercortisolism due to a primary adrenal lesion.
Screening and diagnosis
Clinical features
There are non-significant differences in the clinical fea-
tures of pregnant and non-pregnant women with CS.
In both situations weight gain, hypertension, bruising,
and hirsutism are usually present. Unfortunately, CS is
often not detected until 12–26 weeks of gestation,
partially because changes in physical appearance are
ascribed to pregnancy rather than CS (8,40). On the
other hand, some of the manifestations of CS may be
attributed to complications of pregnancy (gestational
diabetes, preeclampsia, etc.), thus contributing to
delay in the diagnosis of CS (1-3).
Screening tests
In non-pregnant women, screening tests for CS aim at
investigating an enhanced cortisol production or a
deranged diurnal rhythm, or documenting blunted
suppression of cortisol after dexamethasone suppres-
sion. The normal gestational changes in the HPA axis
alter these parameters and complicate the screening
process for CS (8,10,18,28). As reviewed above, these
changes include estrogen-dependent increases in
CBG, increases in plasma cortisol and ACTH, and a 2-
to 3-fold increase in plasma free cortisol and UFC
(8,17,28). The three most useful tools for diagnosis of
CS are the measurement of 24-h UFC levels, low-dose
dexamethasone-suppression tests, and determination
of midnight serum cortisol or late-night salivary corti-
sol (42,62-65). However, none of these tests are per-
fect, every one has different sensitivities and specifici-
ties and several are usually required to enable a better
diagnostic accuracy (66).
There is no significant change when mean
morning plasma cortisol levels are compared in preg-
nant women with CS and in normal pregnancy (17).
Thus, as in the non-pregnant individual, morning plas-
ma cortisol concentrations generally do not establish
the diagnosis of CS during gestation (8).
The nocturnal nadir of plasma cortisol is lost in
CS but is preserved in pregnancy, although with a
higher absolute value (8,17). Elevation of midnight or
late-evening serum cortisol is found in virtually all
non-pregnant women with CS. Similarly, elevation of
midnight or late-evening salivary cortisol levels have
sensitivity of 90–96% and specificity of 96–100% (67-
69). As already mentioned, an increase of salivary cor-
tisol in the late evening may occur in late pregnancy
(12,67). There is only one case report that documents
the potential utility of this noninvasive measure in
pregnancy (70). An elevated midnight or evening plas-
ma cortisol has also helped to confirm hypercorti-
solism in some pregnant women (53,71). However,
no studies have developed a diagnostic threshold for
interpretation of the test in pregnant patients (8).
Measurement of urinary cortisol reflects a
direct assessment of circulating free (biologically
active) cortisol. It has been often considered the gold
standard test for detection of hypercortisolism.
Indeed, in some studies UFC measurement was
shown to have a diagnostic sensitivity and specificity
of 95–100% and 98%, respectively, in the differentia-
tion of CS from obesity (63-66). However, it was
noted that 11% of patients had at least one of four 24-
h collections with values within the normal range
(42). In non-pregnant women, UFC increases above
4-fold normal are virtually diagnostic of CS (66).
During pregnancy, UFC excretion is normal in the
first trimester but it increases up to three times the
upper limit of normal during the second and third
trimesters (13-15). In a recent review, a mean 8-fold
increase (range, 2- to 22-fold) of UFC levels in preg-
nant CS patients was found (3). This overlap of UFC
values in pregnant women with and without CS sug-
gests that only UFC values in the second and third
trimester greater than three times the upper limit of
normal can be taken to indicate CS (3,8).
Two low-dose dexamethasone-suppression tests
(LD-DST) are in widespread use: the overnight and
the 48 h test. In the former, 1 mg of dexamethasone
is given at 23:00 and the concentration of cortisol in
serum measured the next day at 8:00–9:00. In the 48
h test, dexamethasone is given at the dose of 0.5 mg
every 6 h for 2 days at 9:00, 15:00, 21:00, and 3:00
with measurements of cortisol in serum at 9:00 at the
start and end of the test (42,63,64). To exclude
CS the concentration of serum cortisol should be of
1.8 µg/dL (50 nmol/L) or less after either test
(42,66,72). In some series, this cut-off value provided
a sensitivity of 98–100% (44,72). However, in other
series, some 3–8% of patients with Cushing’s disease
retained sensitivity to dexamethasone and showed sup-
pression of serum cortisol to less than 1.8 µg/dL on
either test (73,74).
As commented earlier, suppression of both
plasma and UFC by dexamethasone is blunted in
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pregnancy (8,15). Therefore, the LD-DST has a more
limited utility in pregnancy than in the general popu-
lation because of an increased risk for false-positive
results (8). Nevertheless, pregnancy does not impair
the sensitivity of these tests. Among 17 pregnant
women with CS plasma cortisol levels following LD-
DST ranged from 5.5 to 54.3 µg/dL (152 to 1,499
nmol/liter) (3).
In summary, we recommend a combination of
UFC assessment and measurement of midnight sali-
vary cortisol for screening of CS in pregnancy.
Tests for the differential diagnosis
The main tools for the differential diagnosis are the
determination of plasma ACTH levels, non-invasive
dynamic tests (CRH or desmopressin stimulation tests
and high-dose DST, HD-DST), bilateral inferior pet-
rosal sinus sampling, and imaging studies (42,63-66).
The measurement of plasma ACTH is the first step to
be performed in order to determine the etiology of CS
(42). Hypercortisolism, regardless of the cause,
inhibits ACTH secretion by normal corticotrophs. In
non-pregnant women with CS, ACTH levels are typi-
cally reduced (< 10 pg/mL) in patients with
autonomous adrenal disorders and inappropriately
normal or increased in those with tumoral ACTH pro-
duction (Cushing’s disease or EAS) (42-44).
Eight of 16 patients (50%) with CS caused by
adrenal adenomas or ACTH-independent adrenal
hyperplasia had values greater than 10 pg/mL (3).
Therefore, pregnant patients with adrenal causes of CS
do not consistently have suppressed plasma ACTH
values, probably reflecting effects of placental CRH
that is not suppressed by hypercortisolism (8). As a
result, the recommended diagnostic ACTH thresholds
for adrenal CS in the general population are not valid
in pregnancy and may lead to misdiagnosis (8,62).
The rational of the HD-DST relies on the fact
that, in most situations, the tumoral corticotroph cells
in Cushing’s disease retain some responsiveness to the
negative feedback effects of glucocorticoids whereas
tumors ectopically secreting ACTH and autonomous
adrenal diseases do not (42). The standard or classic
test consists in the determination of serum cortisol or
UFC after the administration of oral dexamethasone at
a dose of 2 mg every 6 h for 48 h. As the 48 h HD-
DST is somewhat cumbersome, a preferable alterna-
tive is the 8-mg overnight DST which involves the
administration of a single 8-mg dose of dexametha-
sone orally at 23:00 with measurement of serum cor-
tisol at 8:00 before and after administration (42,63).
Classically, a cortisol suppression greater than 50% is
indicative of Cushing’s disease. This cut-off value pro-
vides a sensitivity of 60–100% and specificity of
65–100% in the standard test while the corresponding
figures in the overnight test are 60–100% and 59–92%,
respectively (42,75). In our series, serum cortisol sup-
pression > 50% following HD-DST was observed in
78% of patients with Cushing’s disease, in one third of
patients with EAS and in none of those with an
autonomous adrenal disease (44). However, cortisol
suppression > 80% only occurred in patients with
Cushing’s disease. In the Italian multicenter study
(43), cortisol suppression > 80% also had 100% speci-
ficity. A similar response may rarely be found in
patients with EAS (65,76).
Some authors have advocated abandoning HD-
DST due to its limited diagnostic accuracy (76,77).
We believe that this test may be useful when analyzed
together with other non-invasive dynamic tests (CRH
ou desmopressin test) or when cortisol suppression is
> 80%. Moreover, in pregnant patients, the test may
help discriminate adrenal forms of CS from Cushing’s
disease, which may be useful given the difficulties in
interpretation of plasma ACTH and the increased
prevalence of adrenal disorders in pregnancy (8). In a
recent systematic review, no patient with a primary
adrenal cause of CS showed suppression, whereas four
of seven patients (57%) with Cushing’s disease did (3).
The basis of the CRH stimulation test is the fact
that pituitary tumor corticotrophs remain responsive
to CRH stimulation, whereas adrenal tumors and
most ectopic ACTH-secreting tumors do not respond
(42,65,66). The test involves basal sampling for corti-
sol and ACTH followed by intravenous administration
of 1 µg/kg or, more usually, 100 µg of CRH. The
largest individual series set criteria for Cushing’s dis-
ease of 35% increase in ACTH and 20% increase in
cortisol following CRH administration (78). In that
study, the CRH test had a sensitivity and specificity of
91% and 88%, respectively, using cortisol criteria,
whereas the corresponding figures for ACTH criteria
were 93% and 100%, respectively (78).
Ovine CRH is a Food and Drug Administration
(FDA) category C drug, recommended for use in
pregnancy only when absolutely clinically indicated. In
animal studies no teratogenic or adverse behavioral
effects were found after 100 µg human CRH during
organogenesis (79). It was also shown that plasma
ACTH responses to human CRH (1 µg/kg) were
reduced in the third-trimester of normal pregnancies
(29). Although the CRH stimulation test has not been
systematically studied in CS in pregnancy, in the liter-
ature reports there was a substantial rise in plasma cor-
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tisol (44–130%), consistent with surgically confirmed
Cushing’s disease, and no adverse effects were
observed (8,55,71,80).
An alternative to CRH stimulation test is the
desmopressin stimulation test that involves the intra-
venous administration of 10 µg of desmopressin
(43,44). In this test the cortisol responses have a sen-
sitivity of 84% and specificity of 83%, while ACTH
responses provide poorer discrimination with a sensi-
tivity of 77% and specificity of 73% (42). Therefore,
testing with desmopressin is inferior to testing with
CRH in terms of sensitivity and specificity, but this
peptide is cheaper and more easily available worldwide.
We could not find any reports on the use of desmo-
pressin test during pregnancy. Nevertheless, therapy
with desmopressin was shown to be safe for mother
and child in the treatment of gestational diabetes
insipidus (81).
Concerning imaging studies, computed
tomography scans is contraindicated during pregnan-
cy due to the risk of ionizing radiation (71). There-
fore, an adrenal evaluation by magnetic resonance
imaging (MRI) is indicated in patients with sup-
pressed or low-normal ACTH levels. Pituitary MRI
should be performed in all patients with apparent
ACTH-dependent CS, whereas chest and abdominal
MRI should be considered for those with suspected
EAS. A recent consensus statement concluded that
pituitary MRI may provide a definitive diagnosis in
the setting of responses to CRH and dexamethasone
consistent with Cushing’s disease when a greater than
6-mm pituitary adenoma is identified (62). However,
because of potential (but unproven) teratogenic
effects of MRI in the first trimester during organo-
genesis, it is considered contraindicated at that time,
but is considered safe after the 32nd week of gestation.
Between 12 and 32 weeks, the potential and largely
unknown risks of MRI must be balanced with the
potential benefits (8). Moreover, the use of the con-
trast agent gadolinium should be avoided in pregnan-
cy, because it is FDA category C (8). In one series of
non-pregnant individuals, the sensitivity of MRI for
detection of Cushing’s disease decreased from 52%
with contrast to 38% without it (83). It should also be
noted that pituitary MRI will detect an incidental
tumor (≤ 6 mm) in up to 10% of healthy individuals
(84). Furthermore, as the normal pituitary increases
in size up to 2-fold by the third trimester, there may
be an increased number of incidentalomas identified
in pregnancy using these criteria (8).
For pregnant women with CRH and DST
responses consistent with Cushing’s disease, and pitu-
itary lesions larger than 6 mm, usually no additional
testing is necessary (8), just as in the non-pregnant
population (62). For others, an invasive procedure
such as bilateral inferior petrosal sinus sampling
(BIPSS) may be required. The test involves catheteri-
zation of the petrosal sinuses draining the pituitary
gland and simultaneous sampling from these and a
peripheral vein for ACTH measurement before and
after administration of CRH. A central-to-peripheral
ACTH gradient greater than 2 (basal) or 3 (after
administration of CRH or desmopressin) is consistent
with the diagnosis of Cushing’s disease (sensitivity and
specificity of 94%) (82). The perceived risk of ionizing
radiation probably has limited its use in pregnancy,
and we could only find three cases in literature where
BIPPS was performed (3,80). Specific precautions,
including a direct jugular approach for catheter inser-
tion and use of additional lead barrier protection, are
necessary during pregnancy. It has been advocated
that BIPSS should only be considered during preg-
nancy after completion of careful noninvasive assess-
ment and only in centers with special expertise using
the technique. Also, because it is not known whether
pregnant patients with adrenal disease have complete
pituitary suppression, the usual criteria for interpreta-
tion may not exclude these patients (3,8).
In summary, in patients with confirmed CS, a
low plasma ACTH level should prompt imaging of the
adrenals. However, in cases with borderline or elevat-
ed ACTH, a combination of the 8-mg DST and CRH
(or desmopressin) stimulation testing is suggested to
establish the presence of, and distinguish between, the
ACTH-dependent forms. BIPSS may be necessary in
patients with discordant biochemical or imaging find-
ings (8).
Treatment
As already mentioned, untreated CS is associated with
significant maternal morbidity, including diabetes,
hypertension, heart failure, and preeclampsia, and
adverse fetal outcomes, such as premature births,
spontaneous abortions, stillbirth, perinatal death, and
intrauterine growth retardation (1,8,15,40,41). It is
assumed that these outcomes could be prevented by
reducing UFC excretion to the upper part of the range
observed in normal pregnancy (8,14,85). However,
treatment for pregnant patients with CS has been
implemented only sporadically, generally late in the
course of the pregnancy. As a result, the ability of
treatment to prevent adverse outcomes is not well
established. The treatment outcomes of 136 pregnant
women with CS were recently reviewed (3). When no
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active treatment was given, there were 59 live births
(76%) compared with 50 live births (89%) in women
in whom treatment was instituted at a mean gestation-
al age of 20 ± 1 weeks (3). In a patient with apparent
post-surgical remission, the progression to eclampsia
and premature delivery occurred, suggesting that a
successful treatment does not necessarily prevent
adverse outcomes (3).
Adrenalectomy for patients with adrenal tumors
seems to be beneficial and the birth rate after surgery
is approximately 87% (8,34,39,86). Among 40 women
with Cushing’s disease, approximately 20% underwent
transsphenoidal surgery (53), whereas the remainder
was given medical therapy and/or was submitted to
adrenalectomy; one case of unrecognized pregnancy
had external pituitary irradiation (3,8,39). A high pro-
portion, either presenting late in pregnancy or before
modern management, was left untreated (3,8,36,87).
Concerning medical therapy, metyrapone has
been used most often and has had no adverse effects
on maternal hepatic function or fetal development in
the small number of cases reported to date (8,59,88).
However, there is one report of fetal hypoadrenalism
after metyrapone (15). Moreover, this drug may exac-
erbate hypertension and favor progression to
preeclampsia, which may limit its use (8,79,88). Keto-
conazole has been used successfully in three pregnan-
cies without adverse events (89-91), including a
patient who had discontinued contraception while
using ketoconazole (600-1,000 mg/day) for Cush-
ing’s disease (89). Despite known antiandrogenic
effects of ketoconazole through inhibition of aro-
matase activity, a normal male infant was delivered at
the 37th week (89). It should be borne in mind that
ketoconazole crosses the placenta and is teratogenic
and abortifacient in the rat, so that the drug is FDA
category C (3). Cyproheptadine is not recommended
due to lack of efficacy (92). Aminoglutethimide and
mitotane are contraindicated (3,8); the former can
induce fetal masculinization (93) whereas the latter
has teratogenic effects (94).
In summary, surgery is the treatment of choice
for CS in pregnancy, except perhaps late in the third
trimester, with medical treatment being a second
choice. There does not seem to be a rationale for sup-
portive treatment alone (3,8).
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